Piramal Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported over 6-fold jump in its net profit at Rs 273.08 crore for the quarter under review as compared to Rs 41.70 crore for the same quarter in the previous year. Total income of the company increased by 41.26% at Rs 1,578.49 crore for Q4FY24 as compared Rs 1,117.46 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 2-fold jump in its net profit at Rs 101.27 crore for fourth quarter ended March 31, 2024 as compared to Rs 50.11 crore for the same quarter in the previous year. Total income of the company increased by 17.85% at Rs 2,578.74 crore for Q4FY24 as compared Rs 2,188.08 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported over 5-fold jump in net profit at Rs 391.22 crore as compared to Rs 69.50 crore for the previous year. Total income of the company increased by 21.35% at Rs 4,592.17 crore for year under review as compared to Rs 3,784.29 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported net profit at Rs 17.82 crore as compared to net loss of Rs 186.46 crore for the previous year. Total income of the company increased by 14.23% at Rs 8,346.55 crore for year under review as compared to Rs 7,306.66 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |